Evidence map›Paper›PMID 35672697›Full record

ArticleJournal of nanobiotechnology2022

Heart-targeted amelioration of sepsis-induced myocardial dysfunction by microenvironment responsive nitric oxide nanogenerators in situ.

Minzhi Ouyang, Xiangnan Ouyang, Zefang Peng, Minghui Liu, Ganqiong Xu, Zhen Zou, Ming Zhang, Quanliang Shang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Minzhi OuyangDepartment of Ultrasound Diagnosis, Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Xiangnan OuyangDepartment of Ultrasound Diagnosis, Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Zefang PengDepartment of Ultrasound, Hunan Provincial People's Hospital, The First Affiliated of Hunan Normal University, No. 61 Jiefang Road (W), Changsha, China.
Minghui LiuDepartment of Ultrasound Diagnosis, Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Ganqiong XuDepartment of Ultrasound Diagnosis, Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Zhen ZouLaboratory of Chemical Biology and Traditional Chinese Medicine Research, Ministry of Education, College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha, 410081, China.
Ming ZhangDepartment of Ultrasound Diagnosis, Second Xiangya Hospital, Central South University, Changsha, 410011, China. zm7626@csu.edu.cn.
Quanliang ShangDepartment of Ultrasound Diagnosis, Second Xiangya Hospital, Central South University, Changsha, 410011, China. sqljsdh@csu.edu.cn.
Second Xiangya Hospital of Central South University · CNCentral South University · CNHunan Normal University · CNHunan Provincial People's Hospital · CN

Funding

National Natural Science Foundation of China 81801721Natural Science Foundation of Hunan Province 2019JJ50880Natural Science Foundation of Hunan Province,China 2018JJ2578Natural Science Foundation of Hunan Province,China 2020JJ5826
6 · The paper itself

Abstract

backgroundA balanced endogenous level of bioavailable nitric oxide (NO) plays a key role in maintaining cardiovascular homeostasis. The bioactive NO level in the cardiomyocytes was much reduced during sepsis. However, it is clinically challenging for the NO gas therapy due to the lack of spatial and temporal release system with precise control. The purpose of this study is to design a NO-releasing biomaterial with heart-targeted capability responsive to the infectious microenvironment, thus ameliorating lipopolysaccharide (LPS)-induced cardiac dysfunction.

resultsThe heart-targeted NO delivery and in situ releasing system, PCM-MSN@LA, was synthesized using hollow mesoporous silica nanoparticles (MSN) as the carrier, and L-arginine (LA) as the NO donor. The myocardial delivery was successfully directed to heart by specific peptide (PCM) combined with low-intensity focused ultrasound (LIFU) guidance. The myocardial system synthesized NO from the LA released from PCM-MSN@LA in the presence of increased endogenous nitric oxide synthase (NOS) activity induced by LPS. This targeted NO release in situ achieved extraordinary protective effects against LPS-challenged myocardial injury by reducing the recruitment of inflammatory cells, inhibiting oxidative stress and maintaining the mitochondria integrity. In particular, this protection was not compromised by simultaneous circulation collapse as an adverse event in the context.

conclusionsPCM-MSN@LA + LIFU exhibited extraordinary cardioprotective effects against severe sepsis in the hearts of LPS-treated animals without the side effect of NO diffusion. This technology has great potential to be served as a novel therapeutic strategy for sepsis-induced myocardial injury.

Indexed as

Nitric OxideSepsisAnimalsLipopolysaccharidesMyocardiumMyocytes, CardiacLipopolysaccharidesNitric OxideCardiac dysfunction alleviationGas therapyMicroenvironment changeSepsisTargeted delivery

Identifiers

PMID35672697
PMCPMC9171488
OpenAlexW4281952138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.